Scythian Biosciences (TSXV:SCYB) has made its first strategic purchase, the company announced on Monday (July 30). following the sale of its Latin American assets to a major Canadian cannabis licensed producer (LP). The company also revealed a listing change for its stock.

On July 17 Scythian announced a transaction with Aphria (TSX:APH) for all of its interests across the Latin American cannabis market for a price tag of C$193 million in Aphria shares paid to Scythian.


The TSX Venture-listed (TSXV) cannabis company is now eyeing an entry into the Florida market with the purchase of CannCure Investments, a Canadian company currently working on the acquisition of a stake in 3 Boys Farms, a licensed producer in the state.

Rob Reid, Scythian’s CEO, said Florida is becoming one of the “largest and fastest growing medical cannabis markets” in the US.

The prized acquisition of 3 Boys Farms includes its 40,000 square feet of greenhouses for cannabis cultivation and its licenses for retail shops. According to Scythian, the Florida producer is in the process of securing locations across the state.

Scythian drops TSXV to pursue US asset

Due to the potential entry of the US cannabis market, Scythian revealed to investors it will stop offering its stock on the TSXV and will now list on the Canadian Securities Exchange (CSE), an exchange that allows listings to hold assets in the federally illegal market.

The company told investors it expects the exchange transition will be done within the next 10 business days. Currently Scythian’s share trading is halted.

The entire deal, which also includes the acquisition of an undisclosed medical healthcare organization in Florida, consist of a package payment Scythian will initially purchase a 70 percent stake in CannCure and obtain the option for the remaining 30 percent at the same valuation.

According to the company the transaction consists of a C$93.3 million in equity from Scythian common shares, with the addition of a C$43.2 million cash investment into the company.

In order for the Scythian-CannCure transaction to complete, the investment company must close its initial 60 percent stake acquisition of 3 Boys Farms before August 31.

Scythian is also requiring CannCure to hold an option to acquire the balance of the issued and outstanding shares before the end of 2018.

Investor takeaway

Following the dump of its Latin American assets to Aphria, Scythian has elected to seek a stake in the US market which will lead it to swap public exchanges.

Florida has proved to be a worthwhile market for public cannabis operators and a tentative upcoming vote on the legalization of cannabis for adult-use could provide an even higher boost to the assets in the state.

The last available share price for Scythian was C$3.49 on July 25.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less